OTHER NAMES
Levomepromazine, Nozinan

CLASSIFICATION
Antipsychotic - antiemetic - analgesic

*ALLERGY ALERT
See Contraindications

INDICATIONS FOR IV USE

HEALTH CANADA APPROVED¹
• For the relief of moderate to severe pain in nonambulatory patients, and for obstetrical pain and sedation when respiratory depression should be avoided.
• Anxiety, apprehension, restlessness, and sedation before surgery.
• Treatment of nausea and vomiting of central origin.
• Severe psychotic disorders.

CONTRAINDICATIONS¹
• Hypersensitivity to methotrimeprazine or other phenothiazines, as cross allergenicity may occur.
• Hypersensitivity to sulfites; contains sodium sulfite.
• Comatose or depressed states due to CNS depressants.
• Blood dyscrasias, bone marrow depression, liver damage.

CAUTIONS
• Cardiovascular disease, arteriosclerosis, the elderly - initial dosage reduction recommended.¹²
• Patients in whom anti-cholinergic side effects would be detrimental, i.e. prostatic hypertrophy, bladder neck obstruction, narrow angle glaucoma.¹

DRUG INTERACTIONS:
• CNS depressants (barbiturates, narcotic analgesics and antihistamines) - may result in additive CNS depression.
• Epinephrine - results in increased hypotensive effect. If a pressor is required norepinephrine or phenylephrine should be used.¹

PREGNANCY/BREAST FEEDING: Contact pharmacy for most recent information.

ADMINISTRATION

<table>
<thead>
<tr>
<th>MODE</th>
<th>DIRECT INTO IV TUBING</th>
<th>INTERMITTENT INFUSION</th>
<th>CONTINUOUS INFUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO</td>
<td></td>
<td>YES</td>
<td>YES</td>
</tr>
</tbody>
</table>

WHO MAY GIVE

ADULT
All registered nurses

PAEDIATRIC
As above

NEONATE
No information

REQUIREMENTS
None

MONITORING

INTERMITTENT INFUSION

• With first 2 doses and first 2 doses after any dosage increase:
  Baseline BP and HR, then at 5 minutes, then every 15 minutes until stable.

CONTINUOUS INFUSION

• For first 2 hours and first 2 hours after any dosage increase:
  Baseline BP and HR, then at 5 minutes, then every 15 minutes until stable.

RECOMMENDED
• None

RECONSTITUTION
• None required. Available as methotrimeprazine 25 mg/mL - 1 mL ampoule.
COMPATIBILITY/STABILITY
- Compatible in D5W and NS.¹
- Limited stability information available at this time.
- Incompatible with heparin.⁴
- For additional drug-drug compatibility, contact drug information.

ADVERSE EFFECTS

CARDIOVASCULAR
- Orthostatic hypotension may occur at start of therapy. May last up to 2 hours post dose.⁵ Tolerance usually develops.² Appears to be more significant in patients over 40 years of age.⁵

CNS
- Sedation: tolerance usually develops.¹,³
- Moderate anticholinergic effects, e.g. dry mouth, blurred vision, urinary retention.¹
- Extrapyramidal effects, rare.¹

MISCELLANEOUS
- Hypersensitivity reactions (rare), skin reactions due to photosensitivity.¹

DOSE
- Use lowest possible effective dose, adjusting to individual needs and response.²

ADULT
- 12.5 - 50 mg every 4 - 8 hours, as required.⁶
- Elderly - use reduced doses. 5 - 10 mg has been suggested.⁷

PAEDIATRIC
- Limited information available; more commonly given IM.
- 0.2-0.3 mg/kg,⁷ repeat every 4 - 8 hours as required.

NEONATE
- No information available at this time.

RENAL IMPAIRMENT ADJUSTMENTS
- No information available at this time.

HEPATIC IMPAIRMENT ADJUSTMENTS
- Smaller doses may be required.² No specific guidelines available at this time.
- Avoid in severe hepatic impairment.¹

HEMO/PERITONEAL DIALYSIS
- No information available at this time.
METHOTRIMEPRAZINE HYDROCHLORIDE - REFERENCES


